Entrada continues to advance multiple Duchenne exon-skipping programs

As an early investor in Entrada Therapeutics, we are pleased to share that in 2026 Entrada plans to have four clinical-stage programs in Duchenne – for individuals amenable to skipping exon 44, exon 45, exon 50 or exon 51.  

• Exon 44:  They are on track to report data from the first cohort of the ELEVATE-44-201 trial in Q2 2026.  A Phase 1/2 study in the US is planned to start in the first half of 2026.  
• Exon 45:  They are on track to report data from first cohort of the ELEVATE-45-201 trial in mid-2026.  
• Exon 50:  Expect to initiate Phase 1/2 trial in UK and EU by the end of 2026.
• Exon 51:  Expect to submit global regulatory applications in 2026. 

Link to Press Release:  https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-highlights-progress-across-its-portfolio